Projet PET-AlphaSy (Horizon 2020, appel à projets 2018)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.

Mots clés : radiopharmaceutical sciences, alpha synuclein, parkinson s disease  pd, positron emission tomography  pet, molecular imaging you may enter a number of keywords that you consider necess

Participants :
- Johannes Gutenberg University Mainz (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 91284.7 €
- Uppsala University (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 563965.92 €
- Bioarctic ab (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 281982.96 €
- Leiden University (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 161503.53 €
- Novo Nordisk Foundation (Danemark) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ion Beam Applications (Belgium) (Belgique) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Elysia (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 256320.0 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 796859.64 €
- University of Copenhagen (Danemark) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 892566.0 €
- Capital Region of Denmark (Danemark) — Partner, beneficiary, Organismes publics (hors enseignement & recherche), subvention : 297522.0 €
- University of Liège (Belgique) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Tagworks Pharmaceuticals (Netherlands) (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Lundbeck (Denmark) (Danemark) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Positronpharma sa (Chili) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Tübingen (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 758365.2 €
- Eckert & Ziegler (United States) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Pmod technologies gmbh (Suisse) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €